Inovio Pharmaceuticals, Inc.
INO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -44.1% | – |
| Cost of Goods Sold | $0 | $1 | $0 | $1 |
| Gross Profit | $0 | -$1 | $0 | -$1 |
| % Margin | – | – | 100% | -563.1% |
| R&D Expenses | $13 | $14 | $16 | $13 |
| G&A Expenses | $8 | $8,563 | $9 | $0 |
| SG&A Expenses | $8 | $8,563 | $9 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$8,555 | $0 | $0 |
| Operating Expenses | $21 | $22 | $25 | $20 |
| Operating Income | -$21 | -$23 | -$25 | -$20 |
| % Margin | – | – | -38,337% | -17,410.8% |
| Other Income/Exp. Net | -$24 | -$0 | $5 | $1 |
| Pre-Tax Income | -$45 | -$24 | -$20 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45 | -$24 | -$20 | -$19 |
| % Margin | – | – | -30,140.5% | -16,566.4% |
| EPS | -0.87 | -0.61 | -0.51 | -0.7 |
| % Growth | -42.6% | -19.6% | 27.1% | – |
| EPS Diluted | -0.87 | -0.61 | -725.11 | -0.7 |
| Weighted Avg Shares Out | 52 | 39 | 27 | 27 |
| Weighted Avg Shares Out Dil | 52 | 39 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $552 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$45 | -$23 | -$19 | -$19 |
| % Margin | – | – | -29,002.7% | -15,903.3% |